Research programme: apolipoprotein A-I stimulants - KineMed

Drug Profile

Research programme: apolipoprotein A-I stimulants - KineMed

Alternative Names: Acute HDL therapeutic - KineMed; Apo-A1 mimetic peptide for atherosclerosis - KineMed; ApoA-I mimetic lead compound for atherosclerosis and heart disease - KineMed; FX-5A

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator KineMed
  • Class Peptides
  • Mechanism of Action Apolipoprotein A I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Atherosclerosis; Cardiovascular disorders

Highest Development Phases

  • No development reported Atherosclerosis; Cardiovascular disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in USA (IV)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (IV)
  • 11 Apr 2012 Research programme: apolipoprotein A-I stimulants - KineMed is available for licensing as of 11 Apr 2012. http://www.kinemed.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top